Compare IDEXX Laboratories, Inc. (IDXX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Schlumberger NV — how do they compare? IDEXX Laboratories, Inc. trades at $573.33 (market cap $46.22B), while Schlumberger NV trades at $52.95 (market cap $79.67B). The key difference: Schlumberger NV is the larger of the two by market cap, and Schlumberger NV pays a 2.2% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | SLB | |
|---|---|---|
Market Cap | $46.22B | $79.67B |
Sector | Health | Energy |
52-Week High | $766.68 | $58.01 |
52-Week Low | $526.44 | $31.72 |
Enterprise Value | $47.12B | $88.40B |
Dividend Yield | — | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
SLB trades at $52.96, down 0.45% on the day, with a bullish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.55, and maintains a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53%, though margins have softened from prior years. Recent news highlights growth in digital and offshore segments, offset by Middle East challenges.
The outlook for SLB is positive, driven by earnings beats and robust analyst support, but risks include regional volatility and margin pressure. Upside potential exists if digital and production gains accelerate, yet investors must weigh debt levels and geopolitical headwinds against the stock's current valuation near 52-week highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
